In the present study, we assessed if the endogenous platelet inhibitory mechanisms are altered in the early to moderate stages of the atherosclerotic process. Apolipoprotein E deficient mice (ApoE-/-), a mouse model of atherosclerosis, and their wild-type (WT) counterparts were used to assess agonist-stimulated synthesis of prostacyclin (PGI 2 ), inhibition of platelet aggregation ex vivo and intra-platelet cAMP levels. Basal U46619 and ADP -induced platelet aggregation in vitro were increased in ApoE-/-mice at 18-20 weeks in comparison to 8-10 weeks of age. Systemically administered endothelin-1 (ET-1) or bradykinin (BK) inhibited platelet aggregation in a similar fashion in 8-10 week-old ApoE-/-and WT mice, but not in the ApoE-/-mice at 18-20 weeks of age, although both peptides maintained their capacity to increase plasma levels of the PGI 2 .
Introduction
Atherosclerosis is a complex pathology characterized by plaque formation in arteries due to lipid deposition, immune cell accumulation and intimal thickening. Plaque formation can be aggravated when luminal erosion or rupture occur leading to recruitment of circulating platelets (Koenig and Khuseyinova 2007) . Interestingly, platelets have been shown not to be only implicated in thrombotic complications observed in advanced atherosclerotic lesions, but to also play crucial roles in early events of atherogenesis (Chapman 2007) . Indeed, it has been demonstrated that the adhesion of platelets to the endothelium is an event that occurs before the appearance of atherosclerotic lesions (Davi and Patrono 2007) . Adhered and activated platelets participate directly and indirectly in leukocyte recruitment and transmigration toward the endothelium barrier by the expression of adhesion molecules at their surface and the release of pro-inflammatory mediators which consequently interfere with the normal functions of endothelial cells (Lindemann et al. 2007 ). Furthermore, blockade of the adenosine 5'-diphosphate (ADP) P 2 Y 12 receptor, with the antagonist clopidogrel or through its genetic deletion, reduces plaque progression and macrophage infiltration in the aortic arch of ApoE-/-atherosclerotic mice (Heim et al. 2016; Li et al. 2012) . Studies have demonstrated that increased platelet reactivity in patients after percutaneous coronary intervention correlates with an increased risk of cardiovascular events (Gurbel et al. 2005 ). The key role of platelets has been highlighted by clinical trials over the last years showing that the use of platelet P 2 Y 12 receptor antagonists, such as clopidogrel, prasugrel and ticagrelor, given with aspirin in patients with acute coronary syndrome, reduces the D r a f t 5 risk of subsequent events and of cardiovascular mortality. These drugs have become the standard of care in these patients (Tanguay et al. 2013) . Taken together the evidence mentioned above highlight an important implication of platelets at different stages of atherosclerotic lesion progression.
In physiological conditions, the vascular endothelium limits platelet activation. Indeed, this cell monolayer, when stimulated by agonists, produces additional prostacyclin (PGI 2 ) which can inhibit platelet aggregation via cyclic adenosine 3'5'monophosphate (cAMP)-dependent mechanisms (Geiger 2001) . Both endothelin-1 (ET-1) and bradykinin (BK) inhibit platelet aggregation ex vivo in the mouse model (Labonté et al. 2001) and we have shown an increased plasma level of the PGI 2 stable metabolite, 6-keto PGF 1α , following intravenous administration of those two peptides in mice (Carrier et al. 2007 ).
Conversely, in atherosclerotic disease, the endothelium-dependent mechanisms become altered (Schafer and Bauersachs 2008) . In particular, endothelial cell synthetic activities switch from the production of protective vasodilators and platelet inhibitory molecules observed in physiological conditions towards increased synthesis of free radicals and vasoconstrictor agents (Vanhoutte 1997) . The endothelial dysfunction and increased platelet reactivity observed in atherosclerosis prompt the question as to whether endothelial-dependent inhibition of platelet aggregation is still effective in this pathological state. Therefore, the aim of the present study was to determine if the platelet inhibitory properties of PGI 2 -releasing peptides, such as ET-1 and BK, are altered in an animal model of atherosclerosis, the ApoE-/-mouse. This mouse model spontaneously D r a f t 6 develops atherosclerosis under chow diet (Jawień et al. 2004; Nakashima et al. 1994) from early lesions characterized by monocyte adhesion (8-10 weeks old) to foam cell lesions (9-30 weeks old), then to intermediate lesions (>16 weeks old) and finally to fibrous plaque (>21 weeks old) (Jawień et al. 2004 ).
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Materials and methods
Animals
Wild-type (WT) mice (males and females) C57BL/6J were purchased from Charles River (Montreal, QC, Canada). Breeding couples of homozygous ApoE-/-mice (Piedrahita et al. 1992) , on the same genetic background, were initially obtained from Jackson Laboratory (Bar Harbor, ME, USA) and a colony subsequently developed in our facilities. The ApoE-/-genotype was confirmed by the polymerase chain reaction (PCR) method performed on DNA extracts. Mice used for the present study were all maintained on chow diet until the day of experiment (aged 8-10 or 18-20 weeks old).
All animals were kept at constant room temperature (±23°C) and humidity (~78 %) under a controlled light-dark cycle (6H00 AM-6H00 PM).
Animal care and experimentations were approved by the Ethics Committee on Animal
Research of the Université de Sherbrooke, in accordance with the Guide to the Care and Use of Experimental Animals from the Canadian Council on Animal Care.
Surgical procedures in anesthetized animals
Mice were anesthetized with ketamine-xylazine (i.m.: 87 mg kg -1 -13 mg kg -1 ) and then, the jugular vein and carotid artery were cannulated for intravenous (i.v.) injection, blood pressure monitoring and blood sampling as previously reported (Carrier et al. 2007 ).
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Inhibition of platelet aggregation ex vivo
The determination of platelet responses ex vivo to i.v. injection of ET-1 (0.1 and 1 nmol kg -1 ), bradykinin (2.5 and 10 nmol kg -1 ) or the vehicle (PBS) was performed in WT and ApoE-/-mice. Briefly, 5 minutes after the i.v. injection, blood pooled from 2 mice (1.5 mL) was collected using heparin (15 units mL -1 ) as anticoagulant (AC). In another series of experiments, PGI 2 (1 µg kg -1 min -1 ) was infused (10 µL min -1 ) during 5 min, after which blood was immediately collected. Platelet rich (PRP) and poor (PPP) plasma were obtained by centrifugation of the whole blood sample. Adenosine 5'-diphosphate (ADP) was used to induce platelet aggregation in the PRP in order to obtain between 40 % and 50 % platelet aggregation in each control (PBS) experiment.
Platelet aggregation was measured using an aggregometer model 490-2D (Chrono-Log Corporation, Havertown, PA, USA).
Inhibition of platelet aggregation in vitro using an aggregometer
Blood was collected from WT and ApoE-/-mice using sodium citrate 3.8% (w v -1 ) as AC at a 9:1 ratio (2 mice: 1.5 mL of blood). Once the PRP and PPP had been obtained by centrifugation, platelet response to ADP in the PRP was monitored after addition of a nitric oxide (NO) donor, sodium nitroprusside (SNP, 40 µM); a stable prostacyclin analogue, iloprost (100 nM); or saline 0.9 %, as previously reported (Carrier et al. 2007 ).
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Inhibition of platelet aggregation in vitro using a microplate reader
Blood was pooled from two mice of the same strain and PRP and PPP were prepared as described above. The AC used depended on the aggregating agent used, i.e. heparin 15 units mL -1 for U46619, or sodium citrate 3.5% (w v -1 ) at a ratio of 9:1 for ADP. The microplate reader and half-area Costar microplate (Corning Incorporated, Corning, NY, USA) were pre-heated at 37 ºC. The PPP and PRP were simultaneously added to wells already containing either the vehicle (saline 0.9%) or an aggregating agent (ADP or U46619: 1-50 µM). The optical density was measured every 30 seconds over a 30-minute period using a Spectra Max Plus 384 plate reader (Molecular Devices, Sunnyvale, CA, USA) at 560 nm. Changes in the difference of optical density between PPP and PRP, with a correction from wells with PRP + vehicle, were converted to a percentage of platelet aggregation. This method was similar to the one described by Armstrong and colleagues (Armstrong et al. 2008) . Data are expressed as percentage of maximum variation in light transmission from baseline measure using the following equation:
a is for aggregating agent, v is for vehicle, 0 is the initial measurement.
Plasma levels of Prostacyclin
Formation of prostacyclin within the blood of WT and ApoE-/-mice was assessed by measuring its stable metabolite, 6-keto prostaglandin F 1α (6-keto PGF 1α ). Briefly, blood samples were collected after i.v. injection of vehicle (PBS), ET-1 (0.1 nmol kg -1 ) or BK D r a f t (10 nmol kg -1 ) (AC: sodium citrate 3.5% (w v -1 ), ratio 9:1). Plasma samples were obtained by centrifugation and frozen at -80 °C. The 6-keto PGF 1α plasma concentration was then quantified using an enzyme immunoassay (EIA) kit (Cayman Chemical, Ann
Harbor, MI, USA).
Platelet levels of cyclic adenosine 3',5' monophosphate (cAMP)
Blood samples of 800 µL (AC: sodium citrate 3.5 % (w v -1 ) ratio 9:1) were collected 30 seconds after i.v. injection of vehicle (PBS), BK (10 nmol kg -1 ) or iloprost (10 µg kg -1 ).
In another series of experiments, PGI 2 (1 µg kg -1 min -1 ) was infused (10 µl min -1 ) during 5 min, after which blood was immediately collected. PRP at a volume of 200 µL was then obtained after a centrifugation of blood samples for 12 minutes at 120 g. Thereafter, the PRP was centrifuged at 1500 g for 10 minutes to isolate the platelets which were then re-suspended in 100 µL 0.1 M HCl and incubated gently on a shaker for 20 minutes to allow platelet lysis. A further centrifugation at 1000 g for 10 minutes was performed, the supernatant was collected and then snap frozen at -80 ºC until the assay. The assay was performed using a cAMP EIA Kit from Cayman Chemical according to the manufacturer's recommendations, using the acetylation protocol for enhanced sensitivity.
En face analysis of aorta atherosclerotic lesions
Aortas were collected in one piece from the aortic root until the iliac bifurcation. Vessels were cleaned carefully, opened longitudinally and pinned on a black silicone surface. 
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Results
Basal blood parameters in WT and ApoE-/-mice
A significant decrease in the hematocrit was observed in ApoE-/-mice when compared to WT mice at 8-10 weeks of age (WT: 43.9 ± 0.5; ApoE-/-: 40.2 ± 0.9 %, P < 0.01; n = 6-8
for each type of mice) and at 18-20 weeks of age (WT: 44.6 ± 0.2; ApoE-/-: 41.1 ± 0.7 %, P < 0.01; n = 11 for each type of mice). No significant differences were however found between ApoE-/-and WT mice in terms of blood platelet counts (WT: 1,068.6 ± 78.1;
ApoE-/-: 1,323.1 ± 100.0 X 10 3 platelets µL -1 ; n = 6-8 for each mouse strain).
Concentration-dependent platelet aggregation in vitro in response to U46619 and ADP in WT and ApoE-/-mice
The effect of age (8-10 weeks or 18-20 weeks of age) on basal platelet reactivity were investigated in ApoE-/-and WT mice using different concentrations of ADP and U46619, a thromboxane A 2 (TxA 2 ) mimetic. Figure 1 shows that platelet aggregation in response to both agonists did not differ between the two age groups in WT mice ( Fig. 1A and 1C ).
In contrast, in ApoE-/-mice, significant increases in platelet aggregation induced by ADP (Fig. 1B) and U46619 (Fig. 1D) were observed at 18-20 weeks of age compared to 8-10
weeks of age.
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Endothelin-1 and bradykinin-induced inhibition of platelet aggregation ex vivo in WT
and ApoE-/-mice ET-1 (0.1 nmol kg -1 ) and BK (10 nmol kg -1 ) inhibited ADP-induced platelet aggregation ex vivo in a similar fashion in 8-10 week-old WT and ApoE-/-mice (Fig. 2B) . ET-1 (0.1 and 1.0 nmol kg -1) and BK (2.5 and 10 nmol kg -1 ) were also both shown to reduce platelet aggregation (P < 0.01) in 18-20 week-old WT mice, although their anti-platelet effect was statistically significantly reduced in 18-20 week-old ApoE-/-mice (Fig. 3B ).
The corresponding pressor responses to ET-1 and BK were not altered in ApoE-/-mice compared to WT animals ( Figs. 2A and 3A) . found to be greater in ApoE-/-mice than in WT mice at both ages (Fig. 4B ). No differences were however observed between the younger and older ApoE-/-mice in terms of surface covered by lesions (Fig. 4B) . The lesion number and average size also did not differ between age groups (data not shown).
En face analysis of atherosclerotic lesions in the aorta of WT and ApoE-/-mice
D r a f t BK and ET-1 -dependent release of prostacyclin in WT and ApoE-/-(18-20 weeks old) mice
We have previously reported that BK is more potent in stimulating the release of PGI 2 than ET-1 in the plasma of WT mice (Carrier et al. 2007 ). Basal plasma levels of 6-keto PGF 1α were shown not to differ between ApoE-/-and WT mice (Fig. 5A) . Similarly, i.v.
administration of BK (10 nmol kg -1 ) (Fig. 5B) or ET-1 (0.1 nmol kg -1 ) (Fig. 5A) increased plasma levels of 6-keto PGF 1α to the same extent in WT and ApoE -/-mice at 18-20 weeks of age.
Inhibition of platelet aggregation by iloprost, SNP or PGI 2 in WT and ApoE-/-mice
In order to determine whether the loss of the anti-platelet properties of ET-1 and BK observed in the 18-20 week-old ApoE-/-mice ( Fig. 3B) could be explained by a decreased responsiveness of their platelets to inhibitory factors, the anti-platelet effects of a PGI 2 analogue (iloprost) and a nitric oxide donor (SNP) were investigated. Iloprost (100 nM) and SNP (40 µM) were shown to similarly inhibit platelet aggregation in vitro in WT and ApoE-/-mice when directly administered in the PRP (Fig. 5C) . Nonetheless, prostacyclin i.v. infusion failed to inhibit platelet aggregation ex vivo in the 18-20 weekold ApoE-/-mice (Fig. 5D ), similarly to the observations previously made for ET-1 and BK ( Fig 3B) . No differences in terms of the blood pressure lowering effect of the PGI 2 i.v. infusion were observed (Fig. 5E ).
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BK, iloprost or PGI 2 -dependent increase of platelet cAMP in WT and ApoE-/-mice
The cAMP concentration in platelets from WT and ApoE-/-mice (8-10 weeks old and 18-20 weeks old) was measured following i.v. administration of PBS or BK (10 nmol kg -1 ). In addition, cAMP production was monitored in platelets derived from WT or ApoE-/-18-20 week-old mice systemically administered with iloprost (bolus:
10 µg kg -1 ) or PGI 2 (infusion: 1 µg kg -1 min -1 ; 10 µl min -1 ; 5 min). Basal levels of platelet cAMP did not differ by age or genotype groups (Fig. 6 ). Interestingly, BK induced a statistically significant increase in platelet cAMP in all mice, including 18-20 week-old ApoE-/-animals ( Fig. 6) . Furthermore, iloprost and PGI 2 increased intraplatelet cAMP levels in 18-20 week-old ApoE-/-and WT mice (Fig. 6 ).
D r a f t
Discussion
The principal conclusions drawn from the present study is that mice with intermediate atherosclerotic lesions are less responsive than their WT congeners to the platelet inhibitory effects of ET-1 and BK. Interestingly, intravenous administration of BK and PGI 2 did not inhibit platelet aggregation ex vivo in 18-20 week-old ApoE-/-mice despite their capacity to increase intra-platelet levels of cAMP. We also show that the alteration of the platelet inhibitory capacities of ET-1 and BK in ApoE-/-mice progresses with age, which is consistent with the observation of a progressive increase in the response to proaggregating agents (ADP and U46619).
Several groups demonstrated a correlation between atherosclerosis and enhanced platelet reactivity in human (Aoki et al. 2006; Bliden et al. 2007; Gurbel et al. 2005; Rajagopalan et al. 2007 ) as well as in ApoE-/-mice (Eitzman et al. 2000) . Numerous mechanisms have been associated with this enhanced responsiveness, such as enhanced COX-1-derived TxA 2 synthesis (Pfister 2006) , increased production of oxidants (Maytin et al. 1999 ) and loss of functional integrity of the vascular endothelium (Russo et al. 2002) . To our knowledge, however, the present study reports a novel concept of loss of anti-platelet mechanisms within the intermediate, but not early, atherosclerotic processes. were observed following the injection of either agonist, at different doses, in ApoE-/-mice when compared to WT animals.
Interestingly, we found that both BK and ET-1 increase PGI 2 plasma levels in 18-20 week-old WT and ApoE-/-mice suggesting that the agonist-stimulated PGI 2 production is left intact in the latter mouse strain. The PGI 2 IP receptor-dependent platelet inhibitory activity involves activation of adenylyl cyclase and subsequent increase in intra-platelet cAMP (Walter et al. 1993) . In the present study, we show that BK and PGI 2 , when administered systemically, are able to trigger a statistically significant increase in platelet cAMP levels in ApoE-/-of both age groups. Intravenous administration of ET-1 may also increase intra-platelet cAMP in CD-1 control mice (Houde, personal communication), although we did not measure this effect in the present study. Hence, even though PGI 2 is produced and released efficiently in the circulation of older ApoE-/-mice and platelet cAMP levels are increased following BK administration, it remains that BK loses its capacity to inhibit platelet aggregation in these mice. Furthermore, the highest dose of ET-1 (1 nmol kg -1 ), itself a potent cAMP inducer in mouse platelets through PGI 2 release (data not shown), exhibited some platelet inhibitory activity, while BK did not, even though PGI 2 synthesis is much more robust for the latter peptide. These results suggest that the mechanism is not related to the binding of PGI 2 to its IP receptor.
The ApoE-/-mice platelet sensitivity to direct aggregation inhibitors has also been investigated in the present study using a stable PGI 2 analogue, iloprost (Ubatuba et al.
D r a f t 1979). When incubated with platelets in vitro, iloprost inhibited platelet aggregation
significantly in both WT and ApoE-/-mice aged 18-20 weeks. Another study, using washed platelets from 12-week old ApoE-/-mice on a 7-week atherogenic diet, reported a loss of the inhibitory actions of the NO donor glyceryl trinitrate (GTN), but not for the superoxide-insensitive HNO donor isopropylamine NONOate (Bullen et al. 2011) . As BK may also inhibit platelet aggregation ex vivo through NO release (Labonté et al. 2001 ), we also showed that an NO donor, SNP, could inhibit platelet aggregation in vitro in 18-20 week old ApoE-/-mice on a normal diet. These results contrast with our ex vivo results, and suggest that inhibitory mechanisms in platelets are responsive to high concentrations of inhibitory molecules at this stage of the atherosclerotic development.
Thus, the platelet inhibitory activities ex vivo of ET-1 and BK may be competing with short-lived pro-aggregation factors present in plasma. Supporting the role of plasma labile eicosanoids such as TxA 2 , Buga and colleagues found that differences in the platelet inhibitory properties of an ApoA1 peptide mimetic, L-4F, were found between 8-12 month-old WT and ApoE-/-mice in platelet rich plasma but not with washed platelets (Buga et al. 2010 ).
Our results show that in ApoE-/-mice, platelet sensitivity increased with age to both ADP and U46619. The most potent platelet aggregation in our study was observed with the endoperoxide analogue U46619 in 18-20 week-old ApoE-/-mice. TxA 2 synthesis is significantly increased in ApoE-/-mice between 8 and 20 weeks (Praticò et al. 2000) .
The TxA 2 TP receptor, which plays a role in the promotion of the atherosclerotic process (Cayatte et al. 2000; Kobayashi et al. 2004 ), may be activated by a wide variety of D r a f t 20 eicosanoids, including high-concentration PGI 2, but not iloprost (Corriu et al. 2001; Vanhoutte et al. 2017) . In contrast to PGI 2 , iloprost also activates the prostaglandin E 2 receptor 4 (EP4) which is also known to inhibit platelet function, hence providing another mechanism by which iloprost may inhibit platelets (Breyer et al. 2001) . Our results suggest that the TP receptor aggregation pathway may be more sensitive as the atherosclerotic lesions develop into the intermediate stages in ApoE-/-mice. It may thus contribute to the increased ADP and U46619 -induced platelet aggregation observed. It could also contribute to a double action of PGI 2 in these animals, as PGI 2 could activate an over-sensitive TP receptor to counteract the cAMP and cGMP mediated platelet inhibition by BK (Carrier et al. 2007; Labonté et al. 2001; Vanhoutte et al. 2017 ).
Vascular lesions develop spontaneously in ApoE-/-mice and this pathological process can be accelerated by feeding the animals with a Western high-fat diet. The data presented in this study, with ApoE-/-mice under normal diet, illustrates that internal surface covered by lesions in the entire aorta does not progress macroscopically between ages of 8-10 and 18-20 weeks in these mice. In support of this concept, Jawien and coworkers have shown that the aortic sinus lesions progress only slightly between 10 and 20 weeks of age in ApoE-/-mice (Jawień et al. 2004) . It is also of interest that disease in ApoE-/-mice of 18-20 weeks old is characterized by foam cells and intermediate lesions (Nakashima et al. 1994) . Thus, alterations in the reactivity of circulating platelets to TP agonists could take place in the relatively early stages of atherosclerosis progression, before the development of advanced lesions. If our results are to be transposed to humans, our interpretation would suggest that the loss of this protective anti-platelet D r a f t 21 mechanism occurs before the observation of clinical signs associated with advanced atherosclerotic lesions. For instance, young smokers (25 years old) show a decrease of phosphorylated vasodilator stimulated phosphoprotein (VASP-P) levels, a central inhibitory mechanism in platelets, both at an endogenous level and after prostaglandin E 1 incubation, suggesting an early effect of this atherosclerosis risk factor (Assinger et al. 2010) . Thus, the analysis of platelet reactivity to endogenous inhibitory factors could be used as an early marker of the vascular degeneration involved in atherosclerosis.
Inhibitors of the hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase (the statin class), such as atorvastatin and simvastatin, can modulate platelet activation and thrombus formation in mice, although their effects on ex vivo platelet aggregation remains unclear (Moraes et al. 2013; Ni et al. 2012; Owens et al. 2012; Schafer et al. 2005) . As statins can also slow atherosclerotic disease progression (Johnson et al. 2005; Scalia et al. 2001) , the effect of these inhibitors on the endothelium-dependent platelet inhibition in ApoE-/-mice needs to be established. Results of the analysis are expressed as percentage (%) of the total area covered by lesions, in the whole aorta and specifically in the arch (B) *: P < 0.05 vs WT mice. n = 6. 
